Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg
The primary purpose of this study is to determine the steady-state plasma pharmacokinetics (PK) and properties of TR-700 into the pulmonary epithelial lining fluid (ELF) and alveolar macrophages (AM) of healthy volunteers.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
|Official Title:||Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg TR-701 Free Acid in Healthy Volunteers|
- Pharmacokinetic parameters from plasma. [ Time Frame: Day 3 ] [ Designated as safety issue: No ]Pharmacokinetic parameters compared with baseline measurements.
|Study Start Date:||December 2010|
|Study Completion Date:||December 2010|
|Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
Experimental: healthy volunteer
Drug: TR-701 FA
200 mg, oral, once daily for 3 days.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01271998
|United States, Connecticut|
|Trius Investigator Site 001|
|Hartford, Connecticut, United States, 06102|
|Principal Investigator:||David Nicolau, PharmD||Center for Anti-Infective Research and Development|